Cargando…
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Data on safety and immunity elicited by a third booster dose of inactivated COVID-19 vaccine in children and adolescents are scarce. Here we conducted a study based on a double-blind, randomised, placebo-controlled phase 2 clinical trial (NCT04551547) to assess the safety and immunogenicity of a thi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663200/ https://www.ncbi.nlm.nih.gov/pubmed/36376310 http://dx.doi.org/10.1038/s41467-022-34280-y |
_version_ | 1784830820551229440 |
---|---|
author | Wang, Lei Wu, Zhiwei Ying, Zhifang Li, Minjie Hu, Yuansheng Shu, Qun Li, Jing Wang, Huixian Zhang, Hengming Jiao, Wenbin Wang, Lin Zhao, Yuliang Gao, Qiang |
author_facet | Wang, Lei Wu, Zhiwei Ying, Zhifang Li, Minjie Hu, Yuansheng Shu, Qun Li, Jing Wang, Huixian Zhang, Hengming Jiao, Wenbin Wang, Lin Zhao, Yuliang Gao, Qiang |
author_sort | Wang, Lei |
collection | PubMed |
description | Data on safety and immunity elicited by a third booster dose of inactivated COVID-19 vaccine in children and adolescents are scarce. Here we conducted a study based on a double-blind, randomised, placebo-controlled phase 2 clinical trial (NCT04551547) to assess the safety and immunogenicity of a third dose of CoronaVac. In this study, 384 participants in the vaccine group were assigned to two cohorts. One received the third dose at a 10-months interval (cohort 1) and the other one at a 12-months interval (cohort 2). The primary endpoint is safety and immunogenicity following a third dose of CoronaVac. The secondary endpoint is antibody persistence following the primary two-dose schedule. Severities of local and systemic adverse reactions reported within 28 days after dose 3 were mild and moderate in both cohorts. A third dose of CoronaVac increased GMTs to 681.0 (95%CI: 545.2–850.7) in cohort 1 and 745.2 (95%CI: 577.0–962.3) in cohort 2. Seropositivity rates against the prototype were 100% on day 28 after dose 3. Seropositivity rates against the Omicron variant were 90.6% (cohort 1) and 91.5% (cohort 2). A homologous booster dose of CoronaVac is safe and induces a significant neutralising antibody levels increase in children and adolescents. |
format | Online Article Text |
id | pubmed-9663200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96632002022-11-14 Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents Wang, Lei Wu, Zhiwei Ying, Zhifang Li, Minjie Hu, Yuansheng Shu, Qun Li, Jing Wang, Huixian Zhang, Hengming Jiao, Wenbin Wang, Lin Zhao, Yuliang Gao, Qiang Nat Commun Article Data on safety and immunity elicited by a third booster dose of inactivated COVID-19 vaccine in children and adolescents are scarce. Here we conducted a study based on a double-blind, randomised, placebo-controlled phase 2 clinical trial (NCT04551547) to assess the safety and immunogenicity of a third dose of CoronaVac. In this study, 384 participants in the vaccine group were assigned to two cohorts. One received the third dose at a 10-months interval (cohort 1) and the other one at a 12-months interval (cohort 2). The primary endpoint is safety and immunogenicity following a third dose of CoronaVac. The secondary endpoint is antibody persistence following the primary two-dose schedule. Severities of local and systemic adverse reactions reported within 28 days after dose 3 were mild and moderate in both cohorts. A third dose of CoronaVac increased GMTs to 681.0 (95%CI: 545.2–850.7) in cohort 1 and 745.2 (95%CI: 577.0–962.3) in cohort 2. Seropositivity rates against the prototype were 100% on day 28 after dose 3. Seropositivity rates against the Omicron variant were 90.6% (cohort 1) and 91.5% (cohort 2). A homologous booster dose of CoronaVac is safe and induces a significant neutralising antibody levels increase in children and adolescents. Nature Publishing Group UK 2022-11-14 /pmc/articles/PMC9663200/ /pubmed/36376310 http://dx.doi.org/10.1038/s41467-022-34280-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Wang, Lei Wu, Zhiwei Ying, Zhifang Li, Minjie Hu, Yuansheng Shu, Qun Li, Jing Wang, Huixian Zhang, Hengming Jiao, Wenbin Wang, Lin Zhao, Yuliang Gao, Qiang Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents |
title | Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents |
title_full | Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents |
title_fullStr | Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents |
title_full_unstemmed | Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents |
title_short | Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents |
title_sort | safety and immunogenicity following a homologous booster dose of coronavac in children and adolescents |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663200/ https://www.ncbi.nlm.nih.gov/pubmed/36376310 http://dx.doi.org/10.1038/s41467-022-34280-y |
work_keys_str_mv | AT wanglei safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT wuzhiwei safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT yingzhifang safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT liminjie safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT huyuansheng safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT shuqun safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT lijing safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT wanghuixian safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT zhanghengming safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT jiaowenbin safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT wanglin safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT zhaoyuliang safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents AT gaoqiang safetyandimmunogenicityfollowingahomologousboosterdoseofcoronavacinchildrenandadolescents |